Product Description
Mechanisms of Action: Voltage-Gated Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | India | Peru | Taiwan | United States
Approved Indications: None
Known Adverse Events: None
Company: Beijing Renfujunwei Pharmaceutical Technology Development Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20221596 | P2 |
Not yet recruiting |
Other |
None |